VICTORIA UNIVERSITY
MELBOURNE AUSTRALIA

Epigenetic reprogramming of immune cells in women with PCOS impact genes controlling reproductive function

This is the Accepted version of the following publication

Epigenetic reprogramming of immune cells in women with PCOS impact genes controlling reproductive function

Short Title: Epigenetic programming in immune cells of women with PCOS

Danielle Hiam[1], David Simar[2], Rhianna Laker[3], Ali Altıntaş[3], Melanie Gibson-Helm[4], Elly Fletcher[5], Alba Moreno-Asso[1], Adam J Trewin[1], ¶ Romain Barres[3] and ¶* Nigel K Stepto[1,4,6].

[1] Institute for Health and Sport, Victoria University, Melbourne, Australia.

[2] Mechanisms of Disease and Translational Research, School of Medical Sciences, UNSW Sydney, Sydney, Australia.

[3] The Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

[4] Monash Centre for Health Research and Implementation, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.

[5] Baker Heart and Disease Institute, Melbourne, Australia.

[6] Medicine-Western Health School of Medicine, Faculty of Medicine, Dentistry and Health Science, Melbourne, Australia

* Corresponding author

Email: nigel.stepto@vu.edu.au

¶ RB and NS are joint senior authors.

Disclosure statement

The authors declare that they have no competing interests.

Keywords: Polycystic ovary syndrome; DNA methylation; Epigenetics; Inflammation; AMH; Reproduction.

30 **ABSTRACT**

31 **Context.** Polycystic ovary syndrome (PCOS) is a chronic disease affecting reproductive

32 function and whole-body metabolism. While the aetiology is unclear, emerging evidence

33 indicates that the epigenetics may be a contributing factor.

34 **Objective.** To determine the role of global and genome-wide epigenetic modifications in

35 specific immune cells in PCOS compared to controls and if these could be related to clinical

36 features of PCOS.

37 **Design.** Cross-sectional study

38 **Participants.** Women with (n=17) or without PCOS (n=17).

39 **Setting.** Recruited from the general community.

40 **Main Outcome Measure(s).** Isolated peripheral blood mononuclear cells were analysed using

41 multi-colour flow cytometry methods to determine global DNA methylation levels in a cell

42 specific fashion. Transcriptomic and genome-wide DNA methylation analysis was performed

43 on T helper cells using RNA-sequencing and Reduced Representation Bisulfite Sequencing.

44 **Results.** Women with PCOS had lower global DNA methylation in monocytes (p=0.006), T

45 helper (p=0.004), T cytotoxic (p=0.004), and B cells (p=0.03). Specific genome-wide DNA

46 methylation analysis of T helper cells from women with PCOS identified 5,581 differentially

47 methylated CpG sites. Functional gene ontology enrichment analysis showed that genes located

48 at the proximity of differentially methylated CpG sites belong to pathways related to

49 reproductive function and immune cell function. However, these genes were not altered at the

50 transcriptomic level.

51 **Conclusions.** It was shown that PCOS is associated with global, and gene-specific DNA

52 methylation remodelling in a cell-type specific manner. Further investigation is warranted to

53 determine whether epigenetic reprogramming of immune cells is important in determining the

54 different phenotypes of PCOS.

55

Introduction

57 Polycystic ovary syndrome (PCOS) is a metabolic and reproductive disorder with a complex

58 and ill-defined aetiology. It is commonly characterised by increased levels of androgens,

59 inflammatory cytokines, insulin resistance and increased prevalence of sub-fertility [1-3].

60 Familial clustering of PCOS is well documented, providing evidence for a heritable component

61 of the syndrome [4,5]. However, investigations to identify the single nucleotide polymorphisms

62 (SNPs) that may underpin the genetic basis of PCOS have been inconclusive despite recent

63 advances in the field from genome-wide association studies (GWAS) [6-9].

64

65 Emerging evidence suggests a role for altered epigenetic programming in the aetiology of

66 PCOS [10-14]. Genome-wide analysis of transcriptomic, and DNA methylation status have been

67 conducted in adipose tissue and skeletal muscle revealing tissue-specific epigenetic, and

68 transcriptomic differences between women with and without PCOS [13,14]. In adipose tissue,

69 DNA methylation analysis revealed aberrant patterns in pathways involved in adipogenesis,

70 inflammation, glucose regulation and energy metabolism, and these DNA methylation sites

71 corresponded with 30 differentially expressed genes [13]. Similarly, in skeletal muscle,

72 transcriptomic analysis found significantly enriched pathways in immune function, and disease

73 [14]. Finally, both adipose tissue and skeletal muscle showed inflammation as a significantly

74 enriched pathway. This is important because immune cells play a critical role in metabolism,

75 reproductive function, are the main source of inflammatory cytokines and are known to be

76 epigenetically regulated [15-19]. These studies provide important insights into the potential

77 contribution of epigenetic changes to the development of PCOS and rationale for further

78 investigation into epigenetic changes in other cell types that may be affected in PCOS, such as

79 immune cells. In both animal PCOS models, and women with PCOS, altered immune

80   responses, and inflammatory markers have been found in various ovarian tissues, suggesting a

81   role in the pathophysiology of the reproductive features of PCOS [20-22]. Impairment of immune

82   cell function and the infiltration of these cells in insulin sensitive tissues has been shown to

83   cause metabolic impairment and contribute to the onset of type 2 diabetes mellitus (T2DM)

84   [23,24]. Thus, epigenetic remodelling of immune cells can be associated with impaired immune

85   function and contribute to metabolic dysfunction in PCOS [15,25,26].

86

87   Only one study has investigated the contribution of global epigenetic changes in immune cells

88   from women with PCOS [27]. In this study, they measured global DNA methylation (i.e. total,

89   non-site-specific methyl-cytosine abundance) in a mixed population of immune cells known as

90   peripheral blood mononuclear cells (PBMCs) from women with or without PCOS and failed

91   to find any difference [27]. There is increasing evidence supporting that epigenetic changes that

92   occur within specific cell subtypes could be masked by analyses of whole blood [28]. Therefore,

93   cell-type specific global, and genome-wide methylation analysis may reveal a potential role of

94   epigenetics in the immune system especially in PCOS[28-30]. In the present study we hypothesised

95   that specific immune cell populations will present a different DNA methylation profile in

96   women with PCOS compared to women without PCOS[28,31]. Using global and genome-wide

97   DNA methylation analysis we aimed to explore epigenetic remodelling in specific immune

98   cell-subtypes, most notably in T-Helper cells.

99

100   **Materials and methods**

101   **Study population**

102   Premenopausal women *(n=34)* aged between 18-45 years with or without PCOS were recruited

103   from the local community (i.e. a non-clinical population). All participants provided informed

104   written consent. Women with PCOS were confirmed by an endocrinologist (SS or AJ) to have

105 features consistent with the Rotterdam diagnostic criteria based on participant's previous

106 medical records. The Rotterdam criteria was used for confirmation of PCOS with two of the

107 following (i) oligo- or anovulation (ii) clinical (hirsutism and acne) and/or biochemical

108 hyperandrogenism (iii) polycystic ovaries on ultrasound and exclusion of other causes of

109 hyperandrogenism [32,33]. Women without PCOS had no features of PCOS. Exclusion criteria

110 were pregnancy, smoking, T2DM, known cardiovascular disease, asthma and medications

111 affecting endpoint measures including: hormonal contraceptives, insulin sensitising drugs,

112 anti-inflammatories and anti-androgens. This study was approved by the Victoria University

113 Human Research Ethics Committee (HRE 14-138).

114

115 **Clinical measures**

116 All clinical measures were collected in the morning after an overnight fast. For women without

117 PCOS, testing was conducted in the early follicular phase of the menstrual cycle (2-7 days after

118 beginning menses). All women with PCOS had irregular cycles and therefore the testing was

119 conducted in early follicular phase when possible.

120

121 **Lifestyle monitoring**

122 In the seven days preceding the trial, participants recorded their dietary intake *via* a 7-day food

123 diary. Food diaries were analysed by FoodWorks® (Xyris) for the major food groups (grains,

124 fruit, vegetables, protein and dairy), total energy (macronutrients) and fat ratios. Moderate-to-

125 vigorous physical activity was measured via an ActiGraph (GTX3+) accelerometer

126 (Actigraph). Participants wore the monitor on their right hip during waking hours for seven

127 days, except for bathing and swimming. Data was downloaded in 1-minute epochs and non-

128 wear time was defined as at least 20 minutes of zero counts. Daily moderate-to-vigorous

129 physical activity was defined as all wear-time minutes and was calculated based on the

130 Freedson accelerometer age-cut points [34]. Self-reporting physical activity was measured via the

131 International Physical Activity Questionnaire (IPAQ).

132

133 **Anthropometric assessment**

134 Height and weight were measured to calculate body mass index (BMI): [body weight (kg)/

135 height squared (m^2)]. Waist and hip circumference measurements were recorded [35]. Fat mass,

136 abdominal fat mass and fat free mass were measured by dual-energy x-ray absorptiometry

137 (DXA): [GE Lunar iDXA] and analysed by a qualified DXA operator (DH).

138

139 **Fasting blood samples**

140 A sterile polyethylene catheter was inserted into the antecubital vein and baseline blood

141 samples were collected. Plasma and serum were collected in the appropriate blood tubes via

142 centrifugation and stored at -80°C until analysis. Blood for PBMCs isolation was collected in

143 three acid citrate dextrose tubes (BD) and left at room temperature until ficoll gradient

144 separation on the same day as described below [28].

145

146 **Oral glucose tolerance test**

147 After collecting fasting baseline blood samples, participants then underwent an oral glucose

148 tolerance test (OGTT) via ingestion of a 75g glucose drink over a 5 minute period with blood

149 samples collected at 30, 60, 90 and 120 minutes [36]. Blood glucose in plasma was measured on

150 the day by using an automated analyser (YSI 2300 STAT Plus). Blood cell counts were

151 measured on the day by haematology automated analyser (Sysmex).

152

153 **Biochemical analysis**

154 The following assays were completed in house at Victoria University. Plasma insulin

155 concentration was determined by radioimmunoassay according to manufacturer instructions

156 with an intra and inter variability of 4.2% and 3.8% respectively (HI-14K, EMD, Merck

157 Millipore). Results from the OGTT were used to determine both insulin sensitivity and

158 resistance using area under the curve for plasma insulin and glucose concentrations and the

159 homeostasis assessment (HOMA) indices of insulin sensitivity calculated as (fasting insulin x

160 fasting glucose/22.5) [36]. Interleukin-6 (IL-6) was measured using a high sensitivity ELISA with

161 an intra assay variability of 7.6% (ab46042, Abcam). S-adenosylmethionine (SAM) was

162 determined by competitive enzyme immunoassay and had an intra assay variability of 8.8%

163 (STA-672, Cell Biolabs).

164

165 The following assays were completed in the accredited pathology laboratory at Monash Health,

166 Australia. Lipid profiles (Cholesterol, Triglycerides, LDL and HDL) were quantified by

167 automated enzymatic methods (Architect C18000 analyser), high sensitivity C reactive protein

168 (hs-CRP) by a highly sensitive Near Infrared Particle Immunoassay using the Beckman Coulter

169 Synchron LX system Chemistry Analyser (Beckman Coulter). Folate was determined by the

170 Access/DXI Folate assay which is a competitive binding receptor assay performed on the

171 Beckman Coulter Unicel DXI 800 (Beckman Coulter). Homocysteine was measured using a

172 Beckman Coulter Synchron DXC800 system Chemistry Analyser (Beckman Coulter). AMH

173 was analysed using an enzyme-linked immunosorbent assay (A16507, Immunotech, Beckman

174 and Coulter Company). The sex hormone binding globulin (SHBG) assay was performed using

175 a sequential two-step immunoenzymatic ('sandwich') assay carried out on a Beckman Coulter

176 Unicel DXI 800 (Beckman Coulter). Testosterone was measured using high performance liquid

177 chromatography–mass spectrometry (HPLCMS/MS) method using a liquid sample extraction

178 (AB Sciex Triple Quad 5500 LC/MS/MS system). Free androgen index (FAI) was calculated

179   as (total testosterone x 100)/SHBG. Free testosterone (fT) was calculated by the Södergard free

180   Testosterone calculation [37].

181

PBMCs isolation

183   PBMCs were isolated by ficoll gradient as previously described in [28] with some modifications.

184   After centrifugation (1200 x g for 20 mins, brake off) and removal of plasma, the cell

185   suspension was diluted in Roswell Park Memorial Institute medium (RPMI, Thermofisher),

186   supplemented with penicillin/streptomycin and L-glutamine and carefully layered on ficoll in

187   Sepmate™ tubes (Stemcell technologies) in equal volumes and centrifuged. The buffy coat

188   containing PBMCs was collected, washed with RPMI, and resuspended in autologous plasma.

189   Cells were counted on the automated cell counter (TC20™ automated cell counter, Bio-Rad)

190   before being frozen in 10% Cyropreservent DMSO in RPMI overnight in a controlled rate

191   freezing container (CoolCell®, Biocision) and transferred to liquid nitrogen the following day

192   for long-term storage.

193

Global DNA methylation

195   Global methylation in PBMCs was quantified as previously described [28]. Briefly the cells were

196   stained with an antibody cocktail of anti CD3-phycoerytrin conjugated, CD8- and CD14-

197   peridinin chlorophyll conjugated, CD4- and CD19-allophycocyanin conjugated (Becton-

198   Dickinson). Cells were then further stained with anti-5-methylcytosine (5meC, AbD serotec,

199   Bio-Rad) or with its associated isotope control (Mouse, IgG1, BD) labelled with Alexa Flour

200   488 according to manufacturer's instructions (Zenon Alexa Flour 488 Mouse IgG1, Molecular

201   probes, Life Technologies). Cells were incubated (20 min in the dark at room temperature) and

202   then run immediately on the flow cytometer (FACS Calibur, BD). A specific gating strategy

203   (supplemental figure 1) was used to separate the different cell populations and the median

204 fluorescence intensity (MFI) was measured and normalised by the MFI from the isotope

205 controls for each cell population. Data were analysed using FlowJo version 10 (Tree Star) and

206 Cytobank (Cytobank Inc).

207

208 **Cell sorting**

209 Cryopreserved PBMCs were thawed and immediately resuspended in RPMI before being

210 washed and stained with anti-CD3 (APC), anti-CD4 (PE), anti-CD8 (Brilliant Violet or BV

211 510), anti-CD19 (BV421), anti-CD20 (PE-Cyanine or Cy7) and anti-CD14 (APC). All

212 antibodies were sourced from BD Biosciences (supplementary table 1[38]). The stained PBMCs

213 were washed twice in sort buffer [PBS 1% BSA, 25mM HEPES (pH=7.0), 1mM EDTA] before

214 being sorted into four populations (monocytes, T helper, T cytotoxic, and B Cells) using the

215 FACS-Aria (BD).

216

217 **RNA sequencing**

218 Total RNA from T helper cells was extracted using the Qiagen all prep DNA/RNA/miRNA

219 universal kit (#80224, Qiagen) following manufacturer's instructions. Quality of RNA was

220 established using the Agilent RNA 600 Nano kit and Bioanalyser instrument (Agilent

221 Technologies). RNA sequencing was performed according to Illumina TruSeq Stranded Total

222 RNA with Ribo-Zero Gold protocol (Illumina) as previously described [39]. Each library was

223 quantified to ensure optimum cluster densities across every lane of the flow cell using the Qubit

224 dsDNA HS assay kit (Invitrogen). Quality control for base pair size and purity was assessed

225 using the Agilent High Sensitivity DNA chip and Bioanalyser instrument (Agilent

226 Technologies). Each library was diluted to 1nM before being pooled and measured on the

227 Illumina Next Seq 500 (Illumina).

228

Reduced representation bisulphite sequencing (RRBS)

Genomic DNA was extracted from T helper cells using the Qiagen all prep DNA/RNA/miRNA universal kit (#80224, Qiagen) following manufacturer's instructions. RRBS was performed using Diagenode Premium RRBS Kit (#C02030033, Diagenode) following manufacturer's instructions. Each library was quantified using the Qubit dsDNA HS assay kit (Invitrogen) and quality controlled for base pair size and purity using the Agilent High Sensitivity DNA chip and Bioanalyser instrument (Agilent Technologies). Genome-wide DNA methylation of T helper cells was measured on the Illumina Next Seq 500 (Illumina).

Transcriptomic analysis

RNA-seq raw reads were aligned to human genome (hg38) using STAR [40] and gene coverages were computed by featureCounts [41] using Gencode annotation [42]. The ribosomal RNA counts were excluded from the downstream analysis. Libraries with less than 15 million assigned reads were removed from analysis. A generalised linear model ($y \sim 0 + disease$) was fitted for disease factor by using DEseq2 pipeline [43]. Genes with a false discovery rate (FDR) below 0.1 were considered differentially expressed.

Approximately 15 million reads/sample were assigned to genes with 38 genes surviving the expression threshold ($q < 0.1$). Molecular functions and biological processes were established from the Universal Protein Resource (UniProt) which is a comprehensive resource for protein sequence and annotation data. The Kyoto Encyclopaedia of Genes and Genomes (KEGG) database investigated the interaction of molecular pathways that were associated with the identified differentially expressed genes. This provided an *in-silico* indication of the molecular pathways that may be affected in the T helper cells of women with PCOS.

254 **RRBS analysis**

255 RRBS reads were processed with the 'rrbs' setting of Trim Galore v0.3.7 and Cutadapt v1.4.2.

256 Processed reads were mapped to hg38 followed by derivation of CpG methylation using

257 Bismark [44]. Mappings to Y chromosome was removed for the differential methylation analysis.

258 Differential methylation analysis was conducted on site and region level according to the

259 sample groups (PCOS v CON) by using RnBeads pipeline [45]. For each library, SNP-enriched

260 sites were removed and sites with less than 10 counts were masked. Gene ontology (GO)

261 enrichment analysis was conducted to determine significant GO terms using a hypergeometric

262 test and a rank cut-off applied for the top 100 best ranking regions in RnBeads pipeline.

263

264 **Statistical analysis**

265 Data were analysed using IBM SPSS Statistics, version 22 (Armonk, NY). Baseline

266 characteristics are presented as mean ± SD or median (IQR), when data were skewed. The

267 baseline characteristics between PCOS and control groups were compared using student t-tests

268 if data was normally distributed. Data were tested for normality using the Shapiro-Wilk test

269 and when deemed non-normal the Mann Whitney test was used to compare the baseline

270 characteristics. Student t-test were used to examine the difference in global DNA methylation

271 between women with and without PCOS. Statistical significance was accepted when $p < 0.05$.

272 To get insight into the relationship between clinical perturbations and DNA methylation in

273 blood, we performed spearman correlation analyses in women with or without PCOS for each

274 population of PBMCs, assessing the association between body composition, physical activity,

275 dietary intake and hormones with global DNA methylation. After adjusting for multiple

276 comparisons statistical significance was accepted when false discovery rate (FDR) $q \leq 0.1$. The

277 datasets generated and/or analysed during the current study are available in the NCBI's Gene

278 Expression Omnibus (GEO) database through the GEO series accession number GSE130582[46].

279

Results

Clinical and biochemical characteristics

All 17 women with PCOS had irregular cycles or amenorrhea; 14 had clinical or biochemical hyperandrogenism, and 15 had polycystic ovaries on ultrasound. Women without PCOS did not display any of the three clinical features detailed by the Rotterdam criteria [33,47]. Detailed clinical characteristics of the 34 women (n=17 PCOS; n=17 without PCOS) who participated in study are reported in Table 1. There were no differences in age, height, weight, body mass index (BMI), markers of body composition, physical activity, energy, and macronutrient intake between women with or without PCOS (Table 1). There were also no differences in the lipid profile, circulating methyl donors (SAM or homocysteine), cytokines (interleukin or IL-6 and high sensitivity C - reactive protein), or a difference in the fasting and the postprandial response to the oral glucose tolerance test (OGTT) and homeostatic model assessment for assessing insulin resistance (HOMA-IR) (Table 2). There was a tendency for folate to be higher in women with PCOS (p=0.08). Women with PCOS showed a higher area under the glucose curve (p=0.02) during the OGTT compared with women without PCOS, but there was no difference observed for area under the insulin curve between groups (Table 2). Women with PCOS had higher levels of free testosterone (fT) (p<0.01), free androgen index (FAI) (p<0.01) and anti-müllerian hormone (AMH) (p<0.01) (Table 2).

Global DNA methylation

Global DNA methylation analysis of the individual immune cell populations was performed using an antibody that detects methylated cytosine bases coupled with FACS detection [28]. We identified hypomethylation in monocytes (p=0.006), T helper (p=0.004), T cytotoxic (p=0.004), and B Cells (p=0.03) in women with PCOS compared to women without PCOS

12

304   (Figure 1). Furthermore, systemic AMH concentration was associated with global DNA hypo-

305   methylation in T helper (r_s= -0.428, q=0.078), but not in T cytotoxic cells, B cells or monocytes

306   (Table 3). Subset analysis revealed that the AMH associated hypomethylation in T helper cells

307   was only observed in women with PCOS (p=0.035). fT was also associated with DNA

308   hypomethylation in T helper (r_s= -0.381, q<0.087), but not T cytotoxic cells, B cells or

309   monocytes (Table 3). Collectively, our results show a cell-type specific alteration of global

310   DNA methylation in immune cells in PCOS and suggest a correlation with the dysregulated

311   ovarian hormone and hyperandrogenism as indicted by associations with AMH and fT

312   respectively.

313

314   **DNA methylome of T helper cells**

315   To further explore the changes in the methylome of immune cells from women with PCOS, we

316   investigated genome wide methylation levels in sorted T helper cells. We identified 5,581 CpG

317   sites differentially methylated in women with PCOS in T helper cells. Of these sites, only 13

318   were located within promoter regions or gene bodies (8 promoters and 5 gene bodies, Table 4).

319   Gene enrichment analysis of the genes harbouring differentially methylated cytosine's

320   identified gene ontology (GO) terms related to T cell function, and reproductive function

321   including; female pregnancy, response to prolactin, regulation of ovarian follicle development,

322   progesterone receptor signalling pathway, male sex determination and response to steroid

323   hormone (Supplementary Table 2-5[38]). Thus, our results indicate that genes regulating

324   reproductive function are epigenetically remodelled at in specific immune cells.

325

326   **Transcriptomic analysis of T helper cells**

327   To determine if the specific DNA methylation signature we identified in T helper cells is linked

328   to transcriptional changes, we investigated gene expression via RNA sequencing. We found 37

329   genes differentially expressed between women with PCOS (Figure 2), compared to those

330   without PCOS with 33 down-regulated and 4 were upregulated (Table 5). Surprisingly, none

331   of the differentially expressed genes showed changes in DNA methylation as identified by

332   reduced representation bisulphite sequencing (RRBS) analysis. Interestingly a large portion of

333   the differentially expressed transcripts (n=17) were long non-coding RNAs (lncRNA)

334   including pseudogenes, long intergenic non-coding RNA (lincRNA) and Y RNA. The

335   remaining 20 transcripts were protein-coding and related to inflammatory and immune cell

336   function. KEGG analysis revealed that the cyclic guanosine monophosphate (cGMP) signalling

337   and Bone morphogenetic pathway (BMP) signalling pathways were functionally enriched.

338   BMP signalling was upregulated, whereas cGMP signalling was downregulated in women with

339   PCOS. Taken together, our results indicate that epigenetic remodelling of genes related to

340   reproductive function in T helper cells does not seem to be functional at the transcriptomic

341   level in women with PCOS.

342

343   **Discussion**

344   Here, we report that immune cells from women with PCOS have a distinct epigenetic profile,

345   at both *global* and *gene-specific* level. On the global level we found hypomethylation in all

346   PBMCs sub-types. In the specific T-lymphocyte population, the differentially methylated

347   genes that we identified were enriched for gene ontology terms related to T cell function, but

348   also reproductive function, suggesting a role of epigenetic reprogramming in the reproductive

349   defects associated with PCOS.

350

351   **Global DNA Methylation**

352   At the cell-type specific level, PBMCs from women with PCOS display distinct global DNA

353   methylation levels compared to women without PCOS. Only one previous study reported that

14

354 global DNA methylation levels were not different in the total PBMCs fraction from women

355 with PCOS [27]. While we have not measured the global methylation of the total PBMCs fraction

356 in the present study, differences at the cell-type specific level may not be detected when

357 investigating global DNA methylation at the whole PBMC level. This would be consistent with

358 a previous study showing no difference in global DNA methylation in total blood fractions

359 from subjects with type 2 diabetes while global DNA methylation was altered in specific

360 immune cell populations [28]. Further consolidating the importance of measuring global DNA

361 methylation in immune cells in a cell-type specific manner.

362

363 Methylation of DNA is under the control of the one-carbon metabolism notably the methyl

364 donor SAM, which is a cofactor necessary for the transfer of a methyl group to a cytosine base

365 in DNA [48]. To gain insight into the potential relationship between altered global DNA

366 methylation levels in immune cells in PCOS and folate metabolism, we measured key one-

367 carbon metabolites: SAM, homocysteine and folate but found no differences. The lack of

368 association between circulating one-carbon metabolites and global DNA methylation levels in

369 immune cells from women with PCOS suggests that methyl donors may not be the primary

370 driver of the global DNA hypomethylation observed in PCOS. Alternatively it would be

371 interesting to investigate whether the enzymes DNA methyltransferases (DNMTs) or ten-

372 eleven translocation (TET), that are responsible for the transfer of the methyl group to the

373 cytosine base or removal of methyl group respectively, may play a role in the hypomethylation

374 observed in the immune cell populations [49].

375

376 Lifestyle factors such as physical activity and diet have been previously associated with both

377 global, and gene-specific DNA methylation changes [50-52]. Obesity, as measured by BMI, is also

378 associated with distinct DNA methylation patterns [28,31,53,54]. In the present study, we did not

379 find any associations between global methylation and BMI, habitual physical activity or diet

380 (total energy) in any of the cell subsets. These data do not support a role of adiposity, physical

381 activity or caloric intake on the altered global DNA methylation in PBMCs from women with

382 PCOS. Interestingly, we found a negative association between global methylation in T helper

383 cells and circulating levels of AMH. This relationship is only present in women with PCOS

384 who have elevated circulating levels of AMH, suggesting a mechanistic association of this

385 hormone in PCOS and DNA methylation changes in T helper cells. AMH is a member of the

386 transforming growth factor beta (TGF-β) ligand superfamily that is predominantly present in

387 ovaries in healthy women but released into the circulation at elevated levels in PCOS [2,55-60]

388 although there is little literature indicating whether it is a cause or consequence. AMH has been

389 found to cluster with many clinical markers of PCOS including positive correlations with LH,

390 and androgens and negatively with FSH, and glucose levels [59,60]. Furthermore, in women with

391 PCOS, it has been shown that AMH disrupts folliculogenesis by decreasing sensitivity to FSH

392 and thereby inhibiting follicle recruitment, and growth which can result in increased number

393 of pre-antral and antral follicles and the PCO morphology [61,62]. It has also been suggested that

394 circulating AMH may have a functional role outside of the reproductive system [63].

395 Interestingly, in immune cells, members of the TGF-β ligand superfamily are potent regulators

396 of T cell activation and differentiation and control a variety of regulatory epigenetic signals

397 such as chromatin remodelling, histone modification and DNA methylation [64-66]. Based on our

398 observations and considering the literature, we hypothesise that AMH participates in the

399 epigenetic reprogramming of some subpopulations of PBMCs in women with PCOS

400 warranting further research.

401

402 Here we identified a negative correlation between global methylation in T helper cells and fT.

403 In women with PCOS, fT is elevated and is used to diagnose hyperandrogenism in the

404 syndrome[32]. Elevated androgens in animal models are associated with reproductive

405 dysfunction (oligo-anovulation, menstrual disturbances and sub-fertility) that is observed in

406 PCOS [61,67-70]. Androgens have immunomodulatory effects, and elevated androgens are

407 associated with altered immune function that likely impacts reproductive function [71,72].

408 Medawar[73] identified the importance of the immune system in reproduction with further studies

409 identifying the importance in the frequencies of T helper 1 (Th1), T helper 2 (Th2), T helper

410 17 (Th17), and regulatory T (Treg) cells in maintenance of normal ovarian function, and

411 menstrual cycles [73-76]. Interestingly Th1/Th2/Th17 imbalances have been identified in women

412 with PCOS [76-78]. The differentiation of T cells and the ratios of Th1/Th2/Th17/Treg cells appear

413 to be modulated by androgens [72,79-81]. Furthermore, the differentiation of T cells are also

414 modulated by epigenetic mechanisms [15,82,83] and this may be the case in PCOS [72]. Altogether

415 our data complements previous studies indicating the elevated fT was associated with

416 differences in the methylome profile in T helper cells in women with PCOS. Whether

417 hyperandrogenism modulates the epigenome of T helper cells and result in changes to

418 frequency of Th1/Th2/Th17/Treg cells and the reproductive dysfunction in PCOS would be an

419 interesting avenue to explore.

420

421 **DNA methylome, and transcriptomic analysis of T helper cells**

422 We also investigated genome-wide DNA methylation in T helper cells at the single nucleotide

423 resolution and identified differentially methylated cytosine bases at the proximity of genes

424 controlling reproductive function. Specifically, our gene ontology analysis returned terms such

425 as female pregnancy, regulation of ovarian follicle development, and male sex determination.

426 As the altered DNA methylation was present at genes controlling reproductive function in

427 immune cells, this suggests that epigenetic changes may not be tissue specific. Instead, these

428 methylation patterns may occur in multiple tissue-types that are exposed to specific extra-

429   cellular stimuli (possibly elevated AMH levels or elevated androgens), with such exposure

430   potentially occurring *in-utero* or as a result of the development of PCOS over the lifespan [84-

431   86]. With epigenetic reprogramming of genes being related to reproductive function it would be

432   worthwhile investigating other tissues, such as the ovary or neuro-endocrine tissues, where the

433   appropriate transcriptional activators and co-activators are expressed [87,88]. This would provide

434   insights into the role of epigenetic reprogramming at genes controlling reproductive function

435   on ovarian function and sex hormone imbalances in women with PCOS.

436

437   We found no overlap between the transcriptomic, and DNA methylation data. This suggests

438   that the shift in epigenetic signature could be related to differences in the proportions of T-

439   helper subpopulations (T helper 1, T helper 2, T helper 9, T helper 17, follicular T helper,

440   regulatory, naïve, effector, and memory T cells) [89-91]. Previous literature has shown in women

441   with PCOS an increased frequency of the pro-inflammatory Th1 population and a reduced

442   frequency of the in the anti-inflammatory Th2 population [76,78,79]. While we were unable to

443   confirm the frequency of T helper subpopulations, the gene ontology pathway analysis

444   identified differential methylation in the activation and proliferation of different T helper

445   subpopulations suggesting that women with PCOS may indeed have different proportions of

446   the T helper sub-types (supplementary tables 2-5[38]).

447

448   To further consolidate this hypothesis, the transcriptomic analysis of the differentially

449   expressed genes in T helper cells identified pathways that relate to T cell activation and

450   differentiation. Of interest, KEGG analysis revealed that the Bone Morphogenic Protein (BMP)

451   signalling pathway was upregulated in women with PCOS, and BMP, like AMH, is a member

452   of the TGF-β ligand superfamily [92]. The elevated circulating AMH found in our women with

453   PCOS may explain the upregulation of BMP signalling in T helper cells *via* activation of the

454 BMP receptors (BMPR). AMH intracellular signalling works via the BMPR through Smad

455 1/5/8 pathway, that assemble into a complex with Smad 4 (Co-Smad) and translocate into the

456 nucleus activating a range of genes dependent on the cellular context [93-95]. In T cells, the BMP

457 signalling generally regulates activation and differentiation of circulating naïve immune cells,

458 the proliferation of T helper 9, 17, and memory T cells [95,96]. Despite the lack of quantification

459 of T Helper cells frequency in women with and without PCOS, our data provides a potential

460 mechanism by which the upregulated BMP signalling pathway could impact the Th1/Th2

461 balance but warrant further studies [93,97].

462

463 Several differentially expressed genes were associated with inflammation/inflammatory status

464 (Table 5) in women with PCOS compared to those without. This supports the role of

465 inflammation/inflammatory status consistent with previous studies [98], where ovulation requires

466 an appropriate inflammatory reaction [18]. In addition, circulating immune cells and the cytokines

467 they produce are also involved in ovarian function [16,99,100]. Suggesting that the epigenetic marks

468 in our study can alter the transcriptome towards a pro-inflammatory T helper phenotype and

469 suppress ovarian function.

470

471 Many of the differentially expressed genes identified from our transcriptomic analysis were

472 non-coding, with the majority being long non-coding RNAs (lncRNAs) including;

473 pseudogenes, anti-sense RNA and long intergenic non-coding RNAs (lincRNA). LncRNAs are

474 widely expressed and regulate gene expression particularly during development, differentiation

475 and activation of immune cells [101] and have been implicated in the co-morbidities associated

476 with PCOS including T2DM [102,103] and inflammatory disorders [104]. There is also evidence to

477 suggest that lncRNAs can act as a molecular scaffold for epigenetic modifications including

478 DNA methylation and histone modifications [105,106]. Indeed, the lack of overlap in our analysis

479 between DNA methylation and gene expression suggests that other mechanisms such as

480 lncRNA modulating the transcriptomic in PCOS.

481

482 The strength of this study is that this cohort was a well characterised, community recruited

483 group of women with and without PCOS, who were otherwise healthy. We were adequately

484 powered to answer our *apriori* aims with post hoc analysis revealing that we were powered on

485 average 93% for all immune cells populations and had large effect sizes of approximately 0.90

486 [107]. We acknowledge that there is a need for more definitive research into the molecular

487 mechanisms behind each of the different the phenotypes of PCOS. While in the present study

488 we were unable to confidently address the potential epigenetic differences between phenotypes

489 in PCOS, we were able to explore the heterogeneous immune cell population and the unique

490 role these may play in PCOS. These findings provide novel avenues for future research in

491 PCOS including studying the role of methylation in specific immune cells in determining the

492 different phenotypes in PCOS.

493

494 In conclusion, our study in a small, yet well-characterised cohort of women with and without

495 PCOS demonstrates novel epigenomic insights into PCOS. The specific epigenetic

496 reprogramming of genes involved in reproductive function in immune cells from women with

497 PCOS is intriguing and may indicate a role for epigenetic factors in the reproductive

498 dysfunction and sex hormone imbalance associated with PCOS. Finally, we found that global

499 DNA methylation in T helper cells is negatively associated with circulating levels of AMH and

500 fT, suggesting the importance of the cellular milieu (elevated circulating androgens and AMH)

501 in the programming of T helper cells in PCOS and warrants further investigation.

502

519 **References**

520 1. Shorakae S, Boyle J, Teede H. Polycystic ovary syndrome: a common hormonal
521   condition with major metabolic sequelae that physicians should know about. *Intern*
522   *Med J.* 2014;44(8):720-726.
523 2. Cassar S, Teede HJ, Moran LJ, et al. Polycystic ovary syndrome and anti-Mullerian
524   hormone: role of insulin resistance, androgens, obesity and gonadotrophins. *Clin*
525   *Endocrinol (Oxf).* 2014.
526 3. Dumesic DA, Oberfield SE, Stener-Victorin E, Marshall JC, Laven JS, Legro RS.
527   Scientific Statement on the Diagnostic Criteria, Epidemiology, Pathophysiology, and
528   Molecular Genetics of Polycystic Ovary Syndrome. *Endocr Rev.* 2015;36(5):487-525.
529 4. Legro RS, Driscoll D, Strauss JF, 3rd, Fox J, Dunaif A. Evidence for a genetic basis for
530   hyperandrogenemia in polycystic ovary syndrome. *Proc Natl Acad Sci U S A.*
531   1998;95(25):14956-14960.

532   5.   Legro RS, Bentley-Lewis R, Driscoll D, Wang SC, Dunaif A. Insulin resistance in the
533   sisters of women with polycystic ovary syndrome: association with hyperandrogenemia
534   rather than menstrual irregularity. *J Clin Endocrinol Metab.* 2002;87(5):2128-2133.
535   6.   Day FR, Hinds DA, Tung JY, et al. Causal mechanisms and balancing selection inferred
536   from genetic associations with polycystic ovary syndrome. *Nat Commun.* 2015;6.
537   7.   Hayes MG, Urbanek M, Ehrmann DA, et al. Genome-wide association of polycystic
538   ovary syndrome implicates alterations in gonadotropin secretion in European ancestry
539   populations. *Nat Commun.* 2015;6:7502.
540   8.   Shi Y, Zhao H, Shi Y, et al. Genome-wide association study identifies eight new risk
541   loci for polycystic ovary syndrome. *Nat Genet.* 2012;44(9):1020-1025.
542   9.   Chen ZJ, Zhao H, He L, et al. Genome-wide association study identifies susceptibility
543   loci for polycystic ovary syndrome on chromosome 2p16.3, 2p21 and 9q33.3. *Nat
544   Gene.* 2011;43(1):55-59.
545   10.   Shen H-r, Qiu L-h, Zhang Z-q, Qin Y-y, Cao C, Di W. Genome-Wide Methylated DNA
546   Immunoprecipitation Analysis of Patients with Polycystic Ovary Syndrome. *PLoS One.*
547   2013;8(5):e64801.
548   11.   Wang XX, Wei JZ, Jiao J, Jiang SY, Yu DH, Li D. Genome-wide DNA methylation
549   and gene expression patterns provide insight into polycystic ovary syndrome
550   development. *Oncotarget.* 2014.
551   12.   Li S, Zhu D, Duan H, et al. Differential DNA methylation patterns of polycystic ovarian
552   syndrome in whole blood of Chinese women. *Oncotarget.* 2016.
553   13.   Kokosar M, Benrick A, Perfilyev A, et al. Epigenetic and Transcriptional Alterations
554   in Human Adipose Tissue of Polycystic Ovary Syndrome. *Sci Rep.* 2016;6:22883.
555   14.   Nilsson E, Benrick A, Kokosar M, et al. Transcriptional and epigenetic changes
556   influencing skeletal muscle metabolism in women with polycystic ovary syndrome. *J
557   Clin Endocrinol Metab.* 2018.
558   15.   Raghuraman S, Donkin I, Versteyhe S, Barres R, Simar D. The Emerging Role of
559   Epigenetics in Inflammation and Immunometabolism. *Trends Endocrinol Metab.* 2016.
560   16.   Clancy KB, Baerwald AR, Pierson RA. Systemic inflammation is associated with
561   ovarian follicular dynamics during the human menstrual cycle. *PLoS One.*
562   2013;8(5):e64807.
563   17.   Brännström M, Norman RJ. Involvement of leukocytes and cytokines in the ovulatory
564   process and corpus luteum function. *Hum Reprod.* 1993;8(10):1762-1775.
565   18.   Espey LL. Ovulation as an inflammatory reaction--a hypothesis. *Biol Reprod.*
566   1980;22(1):73-106.
567   19.   Bukovsky A, Presl J. Ovarian function and the immune system. *Med Hypotheses.*
568   1979;5(4):415-436.
569   20.   Pate JL, Toyokawa K, Walusimbi S, Brzezicka E. The interface of the immune and
570   reproductive systems in the ovary: lessons learned from the corpus luteum of domestic
571   animal models. *Am J Reprod Immunol.* 2010;64(4):275-286.
572   21.   Figueroa F, Davicino R, Micalizzi B, Oliveros L, Forneris M. Macrophage secretions
573   modulate the steroidogenesis of polycystic ovary in rats: effect of testosterone on
574   macrophage pro-inflammatory cytokines. *Life Sci.* 2012;90(19-20):733-739.
575   22.   Schmidt J, Weijdegard B, Mikkelsen AL, Lindenberg S, Nilsson L, Brannstrom M.
576   Differential expression of inflammation-related genes in the ovarian stroma and
577   granulosa cells of PCOS women. *Mol Hum Reprod.* 2014;20(1):49-58.
578   23.   Zierath JR, Barres RE. Nutritional status affects the epigenomic profile of peripheral
579   blood cells. *Epigenomics.* 2011;3(3):259-260.

580 24. Delamaire M, Maugendre D, Moreno M, Le Goff MC, Allannic H, Genetet B. Impaired
581   leucocyte functions in diabetic patients. *Diabet Med.* 1997;14(1):29-34.
582 25. Wang X, Zhu H, Snieder H, et al. Obesity related methylation changes in DNA of
583   peripheral blood leukocytes. *BMC Medicine.* 2010;8(1):87.
584 26. Kintscher U, Hartge M, Hess K, et al. T-lymphocyte infiltration in visceral adipose
585   tissue: a primary event in adipose tissue inflammation and the development of obesity-
586   mediated insulin resistance. *Arterioscler Thromb Vasc Biol.* 2008;28(7):1304-1310.
587 27. Xu N, Azziz R, Goodarzi MO. Epigenetics in polycystic ovary syndrome: a pilot study
588   of global DNA methylation. *Fertil Steril.* 2010;94(2):781-783.e781.
589 28. Simar D, Versteyhe S, Donkin I, et al. DNA Methylation Is Altered In B And Nk
590   Lymphocytes In Obese And Type 2 Diabetic Human. *Metabolism.* 2014;63(9):1188-
591   1197.
592 29. Adalsteinsson BT, Gudnason H, Aspelund T, et al. Heterogeneity in white blood cells
593   has potential to confound DNA methylation measurements. *PLoS One.*
594   2012;7(10):e46705.
595 30. Glossop JR, Nixon NB, Emes RD, et al. Epigenome-wide profiling identifies
596   significant differences in DNA methylation between matched-pairs of T- and B-
597   lymphocytes from healthy individuals. *Epigenetics.* 2013;8(11):1188-1197.
598 31. Wang X, Zhu H, Snieder H, et al. Obesity related methylation changes in DNA of
599   peripheral blood leukocytes. *BMC Med.* 2010;8:87.
600 32. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group.
601   Revised 2003 consensus on diagnostic criteria and long-term health risks related to
602   polycystic ovary syndrome. *Fertil Steril.* 2004;81(1):19-25.
603 33. Teede HJ, Misso ML, Costello MF, et al. Recommendations from the international
604   evidence-based guideline for the assessment and management of polycystic ovary
605   syndrome. *Fertil Steril.* 2018.
606 34. Trost SG, Pate RR, Sallis JF, et al. Age and gender differences in objectively measured
607   physical activity in youth. *Med Sci Sports Exerc.* 2002;34(2):350-355.
608 35. Swain DP, ed *ACSM's Resource Manual for Guidelines for Exercise testing and
609   Prescription* Seventh ed. Philadelphia: Wolters Kluwer Health /Lippincott Williams &
610   Wilkins; 2014.
611 36. Meyer C, McGrath BP, Teede HJ. Effects of Medical Therapy on Insulin Resistance
612   and the Cardiovascular System in Polycystic Ovary Syndrome. *Diabetes Care.*
613   2007;30(3):471-478.
614 37. Södergard R, Bäckström T, Shanbhag V, Carstensen H. Calculation of free and bound
615   fractions of testosterone and estradiol-17β to human plasma proteins at body
616   temperature. *J Steroid Biochem.* 1982;16(6):801-810.
617 38. Genes controlling reproductive function are epigenetically reprogrammed in immune
618   cells of women with Polycystic Ovary Syndrome- Supplementary Data. 2019.
619   https://figshare.com/s/8088ab38eb90d059dc86.
620 39. Laker RC, Garde C, Camera DM, et al. Transcriptomic and epigenetic responses to
621   short-term nutrient-exercise stress in humans. *Sci Rep.* 2017;7(1):15134.
622 40. Dobin A, Davis CA, Schlesinger F, et al. STAR: ultrafast universal RNA-seq aligner.
623   *Bioinformatics.* 2013;29(1):15-21.
624 41. Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program for
625   assigning sequence reads to genomic features. *Bioinformatics.* 2014;30(7):923-930.
626 42. Harrow J, Frankish A, Gonzalez JM, et al. GENCODE: the reference human genome
627   annotation for The ENCODE Project. *Genome Res.* 2012;22(9):1760-1774.

628   43.   Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for
629   RNA-seq data with DESeq2. *Genome Biol.* 2014;15(12):550.

630   44.   Krueger F, Andrews SR. Bismark: a flexible aligner and methylation caller for
631   Bisulfite-Seq applications. *Bioinformatics.* 2011;27(11):1571-1572.

632   45.   Assenov Y, Muller F, Lutsik P, Walter J, Lengauer T, Bock C. Comprehensive analysis
633   of DNA methylation data with RnBeads. *Nature methods.* 2014;11(11):1138-1140.

634   46.   Genes controlling reproductive function are epigenetically reprogrammed in immune
635   cells of women with Polycystic Ovary Syndrome. 2019.
636   https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE130582.

637   47.   Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised
638   2003 consensus on diagnostic criteria and long-term health risks related to polycystic
639   ovary syndrome (PCOS). *Hum Reprod.* 2004;19(1):41-47.

640   48.   Crider KS, Yang TP, Berry RJ, Bailey LB. Folate and DNA methylation: a review of
641   molecular mechanisms and the evidence for folate's role. *Advances in nutrition*
642   *(Bethesda, Md).* 2012;3(1):21-38.

643   49.   Tajima S, Suetake I, Takeshita K, Nakagawa A, Kimura H. Domain Structure of the
644   Dnmt1, Dnmt3a, and Dnmt3b DNA Methyltransferases. *Adv Exp Med Biol.*
645   2016;945:63-86.

646   50.   Feil R, Fraga MF. Epigenetics and the environment: emerging patterns and
647   implications. *Nature reviews Genetics.* 2012;13(2):97-109.

648   51.   Mendelson MM, Marioni RE, Joehanes R, Liu C, Hedman AK. Association of Body
649   Mass Index with DNA Methylation and Gene Expression in Blood Cells and Relations
650   to Cardiometabolic Disease: A Mendelian Randomization Approach.
651   2017;14(1):e1002215.

652   52.   Rasmussen M, Zierath JR, Barrès R. Dynamic epigenetic responses to muscle
653   contraction. *Drug Discovery Today.* 2014(0).

654   53.   Barres R, Kirchner H, Rasmussen M, et al. Weight Loss after Gastric Bypass Surgery
655   in Human Obesity Remodels Promoter Methylation. *Cell Reports.* 2013;3(4):1020-
656   1027.

657   54.   Jacobsen MJ, Mentzel CM, Olesen AS, et al. Altered Methylation Profile of
658   Lymphocytes Is Concordant with Perturbation of Lipids Metabolism and Inflammatory
659   Response in Obesity. *Journal of diabetes research.* 2016;2016:8539057.

660   55.   Teede H, Misso M, Tassone EC, et al. Anti-Mullerian Hormone in PCOS: A Review
661   Informing International Guidelines. *Trends Endocrinol Metab.* 2019.

662   56.   Cook CL, Siow Y, Brenner AG, Fallat ME. Relationship between serum mullerian-
663   inhibiting substance and other reproductive hormones in untreated women with
664   polycystic ovary syndrome and normal women. *Fertil Steril.* 2002;77(1):141-146.

665   57.   Siow Y, Kives S, Hertweck P, Perlman S, Fallat ME. Serum Mullerian-inhibiting
666   substance levels in adolescent girls with normal menstrual cycles or with polycystic
667   ovary syndrome. *Fertil Steril.* 2005;84(4):938-944.

668   58.   Lie Fong S, Laven JSE, Duhamel A, Dewailly D. Polycystic ovarian morphology and
669   the diagnosis of polycystic ovary syndrome: redefining threshold levels for follicle
670   count and serum anti-Mullerian hormone using cluster analysis. *Hum Reprod.*
671   2017;32(8):1723-1731.

672   59.   Sova H, Unkila-Kallio L, Tiitinen A, et al. Hormone profiling, including anti-Mullerian
673   hormone (AMH), for the diagnosis of polycystic ovary syndrome (PCOS) and
674   characterization of PCOS phenotypes. *Gynecol Endocrinol.* 2019;35(7):595-600.

675 60. Tata B, Mimouni NEH, Barbotin AL, et al. Elevated prenatal anti-Mullerian hormone
676 reprograms the fetus and induces polycystic ovary syndrome in adulthood. *Nat Med.*
677 2018;24(6):834-846.
678 61. Lebbe M, Woodruff TK. Involvement of androgens in ovarian health and disease. *Mol*
679 *Hum Reprod.* 2013;19(12):828-837.
680 62. Catteau-Jonard S, Jamin SP, Leclerc A, Gonzalès J, Dewailly D, di Clemente N. Anti-
681 Mullerian Hormone, Its Receptor, FSH Receptor, and Androgen Receptor Genes Are
682 Overexpressed by Granulosa Cells from Stimulated Follicles in Women with Polycystic
683 Ovary Syndrome. *The Journal of Clinical Endocrinology & Metabolism.*
684 2008;93(11):4456-4461.
685 63. Stepto NK, Moreno-Asso A, McIlvenna LC, Walters KA, Rodgers RJ. Molecular
686 Mechanisms of Insulin Resistance in Polycystic Ovary Syndrome. Unraveling the
687 Conundrum in Skeletal Muscle? *J Clin Endocrinol Metab.* 2019.
688 64. Bai J, Xi Q. Crosstalk between TGF-beta signaling and epigenome. *Acta biochimica et*
689 *biophysica Sinica.* 2017:1-8.
690 65. Konkel JE, Zhang D, Zanvit P, et al. Transforming Growth Factor-beta Signaling in
691 Regulatory T Cells Controls T Helper-17 Cells and Tissue-Specific Immune
692 Responses. *Immunity.* 2017;46(4):660-674.
693 66. Li MO, Wan YY, Sanjabi S, Robertson A-KL, Flavell RA. Transforming Growth
694 Factor-β regulation of immune responses. *Annu Rev Immunol.* 2006;24(1):99-146.
695 67. Teede H, Deeks A, Moran L. Polycystic ovary syndrome: a complex condition with
696 psychological, reproductive and metabolic manifestations that impacts on health across
697 the lifespan. *BMC Med.* 2010;8:41.
698 68. Bishop CV, Reiter TE, Erikson DW, et al. Chronically elevated androgen and/or
699 consumption of a Western-style diet impairs oocyte quality and granulosa cell function
700 in the nonhuman primate periovulatory follicle. *J Assist Reprod Genet.* 2019.
701 69. Catteau-Jonard S, Dewailly D. Pathophysiology of polycystic ovary syndrome: the role
702 of hyperandrogenism. *Front Horm Res.* 2013;40:22-27.
703 70. Jonard S, Robert Y, Cortet-Rudelli C, Pigny P, Decanter C, Dewailly D. Ultrasound
704 examination of polycystic ovaries: is it worth counting the follicles? *Hum Reprod.*
705 2003;18(3):598-603.
706 71. Segner H, Verburg-van Kemenade BML, Chadzinska M. The immunomodulatory role
707 of the hypothalamus-pituitary-gonad axis: Proximate mechanism for reproduction-
708 immune trade offs? *Dev Comp Immunol.* 2017;66:43-60.
709 72. Walecki M, Eisel F, Klug J, et al. Androgen receptor modulates Foxp3 expression in
710 CD4+CD25+Foxp3+ regulatory T-cells. *Mol Biol Cell.* 2015;26(15):2845-2857.
711 73. Medawar P. Some immunological and endocrinological problems raised by the
712 evolution of viviparity in vertebrates *Symp Soc Exp Biol.* 1953.
713 74. Polese B, Gridelet V, Araklioti E, Martens H, Perrier d'Hauterive S, Geenen V. The
714 Endocrine Milieu and CD4 T-Lymphocyte Polarization during Pregnancy. *Front*
715 *Endocrinol (Lausanne).* 2014;5:106.
716 75. Abrams ET, Miller EM. The roles of the immune system in Women's reproduction:
717 Evolutionary constraints and life history trade-offs. *Am J Phys Anthropol.*
718 2011;146(S53):134-154.
719 76. Omu AE, Al-Azemi MK, Makhseed M, et al. Differential expression of T-helper
720 cytokines in the peritoneal fluid of women with normal ovarian cycle compared with
721 women with chronic anovulation. *Acta Obstet Gynecol Scand.* 2003;82(7):603-609.

722   77.   Nasri F, Doroudchi M, Namavar Jahromi B, Gharesi-Fard B. T Helper Cells Profile and
723   CD4+CD25+Foxp3+Regulatory T Cells in Polycystic Ovary Syndrome. *Iran J*
724   *Immunol.* 2018;15(3):175-185.

725   78.   Qin L, Xu W, Li X, et al. Differential Expression Profile of Immunological Cytokines
726   in Local Ovary in Patients with Polycystic Ovarian Syndrome: analysis by Flow
727   Cytometry. *Eur J Obstet Gynecol Reprod Biol.* 2016;197:136-141.

728   79.   Gong P, Shi B, Wang J, et al. Association between Th1/Th2 immune imbalance and
729   obesity in women with or without polycystic ovary syndrome. *Gynecol Endocrinol.*
730   2018;34(8):709-714.

731   80.   Olsen NJ, Kovacs WJ. Effects of androgens on T and B lymphocyte development.
732   *Immunol Res.* 2001;23(2-3):281-288.

733   81.   Trigunaite A, Dimo J, Jørgensen TN. Suppressive effects of androgens on the immune
734   system. *Cell Immunol.* 2015;294(2):87-94.

735   82.   Floess S, Freyer J, Siewert C, et al. Epigenetic Control of the foxp3 Locus in Regulatory
736   T Cells. *PLoS Biol.* 2007;5(2):e38.

737   83.   Lee DU, Agarwal S, Rao A. Th2 Lineage Commitment and Efficient IL-4 Production
738   Involves Extended Demethylation of the IL-4 Gene. *Immunity.* 2002;16(5):649-660.

739   84.   Barry JA, Kay AR, Navaratnarajah R, et al. Umbilical vein testosterone in female
740   infants born to mothers with polycystic ovary syndrome is elevated to male levels. *J*
741   *Obstet Gynaecol.* 2010;30(5):444-446.

742   85.   Jennewein MF, Abu-Raya B, Jiang Y, Alter G, Marchant A. Transfer of maternal
743   immunity and programming of the newborn immune system. *Semin Immunopathol.*
744   2017;39(6):605-613.

745   86.   Hart R, Sloboda DM, Doherty DA, et al. Circulating maternal testosterone
746   concentrations at 18 weeks of gestation predict circulating levels of antimullerian
747   hormone in adolescence: a prospective cohort study. *Fertil Steril.* 2010;94(4):1544-
748   1547.

749   87.   Fabre O, Ingerslev LR, Garde C, Donkin I, Simar D, Barres R. Exercise training alters
750   the genomic response to acute exercise in human adipose tissue. *Epigenomics.*
751   2018;10(8):1033-1050.

752   88.   Donkin I, Barres R. Sperm epigenetics and influence of environmental factors.
753   *Molecular metabolism.* 2018.

754   89.   Sellars M, Huh JR, Day K, et al. Regulation of DNA methylation dictates Cd4
755   expression during the development of helper and cytotoxic T cell lineages. *Nat*
756   *Immunol.* 2015;16(7):746-754.

757   90.   Li Y, Chen G, Ma L, et al. Plasticity of DNA methylation in mouse T cell activation
758   and differentiation. *BMC Mol Biol.* 2012;13:16.

759   91.   Qiu H, Wu H, Chan V, Lau CS, Lu Q. Transcriptional and epigenetic regulation of
760   follicular T-helper cells and their role in autoimmunity. *Autoimmunity.* 2017;50(2):71-
761   81.

762   92.   Akhurst RJ, Hata A. Targeting the TGFbeta signalling pathway in disease. *Nature*
763   *reviews Drug discovery.* 2012;11(10):790-811.

764   93.   Josso N, Clemente Nd. Transduction pathway of anti-Müllerian hormone, a sex-
765   specific member of the TGF-β family. *Trends Endocrinol Metab.* 2003;14(2):91-97.

766   94.   Nohe A, Hassel S, Ehrlich M, et al. The mode of bone morphogenetic protein (BMP)
767   receptor oligomerization determines different BMP-2 signaling pathways. *J Biol Chem.*
768   2002;277(7):5330-5338.

769   95.   Martinez VG, Sacedon R, Hidalgo L, et al. The BMP Pathway Participates in Human
770   Naive CD4.sup.+ T Cell Activation and Homeostasis. *PLoS One.* 2015;10.

771   96.   Veldhoen M, Uyttenhove C, van Snick J, et al. Transforming growth factor-β
772   'reprograms' the differentiation of T helper 2 cells and promotes an interleukin 9–
773   producing subset. *Nat Immunol.* 2008;9:1341.
774   97.   Yoshioka Y, Ono M, Osaki M, Konishi I, Sakaguchi S. Differential effects of inhibition
775   of bone morphogenic protein (BMP) signalling on T-cell activation and differentiation.
776   *Eur J Immunol.* 2012;42(3):749-759.
777   98.   Su N-J, Ma J, Feng D-F, et al. The peripheral blood transcriptome identifies
778   dysregulation of inflammatory response genes in polycystic ovary syndrome. *Gynecol
779   Endocrinol.* 2017:1-5.
780   99.   Clancy KB, Klein LD, Ziomkiewicz A, Nenko I, Jasienska G, Bribiescas RG.
781   Relationships between biomarkers of inflammation, ovarian steroids, and age at
782   menarche in a rural Polish sample. *Am J Hum Biol.* 2013;25(3):389-398.
783   100.   Clancy KB, Baerwald AR, Pierson RA. Cycle-phase dependent associations between
784   CRP, leptin, and reproductive hormones in an urban, Canadian sample. *Am J Phys
785   Anthropol.* 2016;160(3):389-396.
786   101.   Atianand MK, Fitzgerald KA. Long non-coding RNAs and control of gene expression
787   in the immune system. *Trends Mol Med.* 2014;20(11):623-631.
788   102.   Kornfeld JW, Bruning JC. Regulation of metabolism by long, non-coding RNAs.
789   *Frontiers in genetics.* 2014;5:57.
790   103.   Knoll M, Lodish HF, Sun L. Long non-coding RNAs as regulators of the endocrine
791   system. *Nat Rev Endocrinol.* 2015;11(3):151-160.
792   104.   Carpenter S, Aiello D, Atianand MK, et al. A long noncoding RNA mediates both
793   activation and repression of immune response genes. *Science.* 2013;341(6147):789-
794   792.
795   105.   Spitale RC, Tsai MC, Chang HY. RNA templating the epigenome: long noncoding
796   RNAs as molecular scaffolds. *Epigenetics.* 2011;6(5):539-543.
797   106.   Rinn JL, Chang HY. Genome Regulation by Long Noncoding RNAs. *Annu Rev
798   Biochem.* 2012;81(1):145-166.
799   107.   Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: a flexible statistical power
800   analysis program for the social, behavioral, and biomedical sciences. *Behav Res
801   Methods.* 2007;39(2):175-191.
802

803

Legends

Table 1: Anthropometric data and lifestyle characteristics.

Table 2: Metabolic and reproductive profile of participating women with and without PCOS.

Table 3: Spearman correlations of *apriori* co-variates with global DNA methylation in T helper cells, T cytotoxic cells, monocytes, B cells across all participants.

Table 4: Genes and promoters carrying differentially methylated CpGs in T helper cells from women with PCOS compared to women without PCOS.

Table 5: Differentially expressed genes in T helper cells from women with PCOS compared to women without PCOS.

Figures

Figure 1: Lower 5-methylcytosine levels in monocytes, T helper, T cytotoxic and B cells in women with PCOS. Comparison of 5-methylcytosine median fluorescence intensity (MFI) between women with PCOS (square) and women without PCOS (circle). MFI normalised by the MFI from the isotope control. Significantly different from control *p<0.05 **p<0.01

Figure 2: Volcano plots representing differentially expressed genes in T helper cells of women with PCOS compared to women without PCOS. Red circles highlight differentially expressed genes. False discovery rate (FDR) q<0.1.

Tables

Table 1: Anthropometric data and lifestyle characteristics.

Clinical features	Sample Size n	Without PCOS Mean ± SD Median [IQR]	With PCOS Mean ± SD Median [IQR]	p
General characteristics				
Age (years)	34	30.1 ± 6.6	28.9 ± 4.8	p=0.6
Height (cm)	34	165 ± 7.2	162 ± 4.7	p=0.3
Weight (kg)	34	70.5 ± 16.8	71.5 ± 18.2	p=0.9
BMI (kg/m^2)	34	25.5 ± 5.4	26.6 ± 6.9	p=0.6
WHR	32	0.85 [0.8, 1.0]	0.80 [0.8, 0.9]	p=0.2
Body fat (%)	31	32.3 [25.9, 40.5]	37.7 [31.8, 41.8]	p=0.3
Physical activity				
PA (IPAQ-mins.week)	31	172 [15.0, 427.5]	165 [40.0, 255.0]	p=0.6
PA (Accel-mins.day)	30	47.0 [45.5, 48.5]	47.0 [46.0, 50.5]	p=0.6
Food intake				
Energy (g)	31	8269 [7033, 11402]	7744 [5509, 8885]	p=0.2
Saturated fats (g)	31	28.0 [23.0, 50.0]	21.5 [17.2, 30.3]	p=0.07
Carbohydrates (g)	31	198 [157, 278]	171 [144, 220]	p=0.2
Sugar (g)	31	70.0 [56.5, 118]	67.5 [51.0, 123]	p=0.6

831 BMI, body mass index; WHR, waist-to-hip ratio; IPAQ, International Physical Activity

832 Questionnaire; MVPA; Moderate Vigorous Physical Activity; PA; physical activity.

833

834 **Table 2: Metabolic and reproductive profile of participating women with and without**

835 **PCOS.**

Clinical features	Sample Size n	Without PCOS Mean±SD Median [IQR]	With PCOS Mean±SD Median [IQR]	p
Lipid profile				
Cholesterol (mmol/L)	30	4.2 ± 0.7	4.4 ± 0.7	p=0.5

Triglycerides (mmol/L)	30	0.6 [0.6, 0.9]	0.8 [0.5, 1.0]	p=0.6
HDL(mmol/L)	30	1.5 ± 0.3	1.5 ± 0.3	p=1.0
LDL (mmol/L)	30	2.5 ± 0.6	2.4 ± 0.7	p=0.6
OGTT				
Fasting glucose (mmol/L)	34	4.9 [4.8, 5.4]	4.9 [4.6, 5.3]	p=0.4
Fasting insulin (pmol/L)	34	72.8 [56.2, 89.4]	68.5 [47.2, 102.4]	p=0.9
2hr glucose (mmol/L)	34	4.75 [4.5, 5.4]	5.5 [4.6, 5.8]	p=0.2
2hr insulin (pmol/L)	34	278 [207, 399]	309 [165, 737]	p=0.5
AUC Glucose (mmol/L)	33	665.8 ± 75.4	783.7 ± 167.8	p=0.02
AUC Insulin (mmol/L)	33	48012 ± 18367	66180 ± 40350	p=0.11
HOMA	34	2.65 [2.0, 3.2]	2.41 [1.7, 4.4]	p=0.9
Reproductive markers				
fT (pM)	34	23.2 [17.7, 31.2]	10.80 [10.3, 14.1]	p<0.001
SHBG (nmol/L)	34	62.1±21.5	63.4±38.4	p=0.9
FAI	34	1.42 [1.4, 2.2]	3.17 [2.2, 5.3]	p<0.001
AMH (pmol/L)	33	18.9 [10.8, 31.1]	48.6 [37.7, 74.6]	p<0.001
Systemic methyl substrate/donors				
SAM (µg/mL)	32	7.7 [5.4, 8.3]	6.9 [6.0, 12.8]	p=0.7
Folate (nmol/L)	33	29.9 [23.2, 37.5]	37.3 [23.4, 45.8]	p=0.08
Homocysteine	33	9.0 [6.9, 10.1]	7.1 [6.4, 9.7]	p=0.3
Cytokines				
HsCRP (mg/L)	30	1.3 [0.5, 3.3]	1.4 [0.6, 4.5]	p=0.7
IL-6 (pg/ml)	31	1.8 [1.3, 3.0]	2.1 [1.5, 2.9]	p=0.3
Cell counts				
WBC (µL)	31	5335 ± 1229	5750 ± 1497	p=0.4

836 OGTT, oral glucose tolerance test; AUC, area under the curve; HOMA, homeostatic model

837 assessment, fT, free testosterone; SHBG, Sex Hormone Binding Globulin; FAI, Free Androgen

838 Index; AMH, Anti-Müllerian Hormone; IL-6, Interleukin-6; HsCRP, High sensitivity C-

839 reactive protein; SAM, S-adenosylmethionine.

Table 3: Spearman correlations of *apriori* co-variates with global DNA methylation in T

helper cells, T cytotoxic cells, monocytes, B cells across all participants.

Covariate		Spearman Correlation			
		T helper	T cytotoxic	Monocytes	B Cells
BMI (kg/m²)	r_s	0.007	0.021	0.140	0.143
	p-Value	0.967	0.905	0.430	0.420
	FDR q-value	0.967	0.900	0.516	0.504
PA (MVPA mins.day)	r_s	-0.139	-0.166	-0.165	-0.213
	p-Value	0.463	0.380	0.383	0.259
	FDR q-value	0.694	0.735	0.5164	0.504
Energy (g)	r_s	0.070	-0.068	-0.069	-0.095
	p-Value	0.708	0.716	0.712	0.612
	FDR q-value	0.846	0.852	0.8546	0.612
AMH (pmol/L)	r_s	**-0.428**	-0.317	-0.286	-0.191
	p-value	**0.013**	0.072	0.106	0.288
	FDR q-value	**0.078**	0.432	0.351	0.504
fT (pM)	r_s	**-0.381**	-0.237	-0.278	-0.175
	p-Value	**0.029**	0.183	0.117	0.330
	FDR q-value	**0.087**	0.549	0.351	0.504
AUC glucose (mmol/L)	r_s	-0.160	-0.124	-0.152	-0.154
	p-Value	0.373	0.493	0.399	0.393
	FDR q-value	0.694	0.735	0.516	0.504

BMI, Body Mass Index; MVPA, Moderate Vigorous Physical Activity; PA; physical activity;

AMH, Anti-Müllerian Hormone; AUC, area under the curve. r_s, Spearman's Rho; fT, free

testosterone. Significance was considered when false discovery rate (FDR) q<0.1.

Table 4: Genes and promoters carrying differentially methylated CpGs in T helper cells from women with PCOS compared to women

without PCOS.

Genes				
Gene symbol	**Gene Name**	**ENSEMBL Gene ID**	**Chromosome**	**Function and gene type**
COX6CP15	*cytochrome c oxidase subunit 6C pseudogene 15*	ENSG000000228092	chr10	pseudogene
SCGB1D4	*secretoglobin family 1D member 4*	ENSG0000001 97745	chr11	Regulation of chemotactic cell migration and invasion.
NA	*AC025678.3*	ENSG000000279092	chr15	TEC (To be experimentally confirmed) protein tyrosine kinase-involved in T cell signalling and activation
NA	*AP006565.1*	ENSG000000279092	chr18	anti-sense RNA
NA	*AC104301.2*	N/A	chr20	ncRNA
Promoter of genes				
Gene symbol	**Gene Name**		**Chromosome**	**Function and gene type**
WBP11P1	*WW domain binding protein 11 pseudogene 1*	ENSG000000260389	chr2	pseudogene
SCGB3A2	s*ecretoglobin family 3A member 2*	ENSG0000001 64265	chr5	receptor-mediated endocytosis

COX6CP15	cytochrome c oxidase subunit 6C pseudogene 15	ENSG000002 28092	chr10	pseudogene
SCGB1D4	secretoglobin family 1D member 4	ENSG000001 97745	chr11	regulation of chemotactic cell migration and invasion.
OVCH1	ovochymase 1	ENSG000001 87950	chr12	serine-type endopeptidase activity, hydrolase activity, metal ion binding, proteolysis
NA	AP006565.1	ENSG000002 65737	chr18	anti-sense RNA
NA	AC104301.2	N/A	chr20	ncRNA
IGLJ2	immunoglobulin lambda joining 2	ENSG000002 11676	chr22	Immunoglobin

847

848 **Table 5: Differentially expressed genes in T helper cells from women with PCOS compared to women without PCOS.**

Down regulated genes in women with PCOS							
Gene name	Gene symbol	ENSEMBL Gene ID	log2Fold Change	padj	Gene type	Molecular function	Molecular process
NA	AC138969.2	ENSG00000277920	-7.7	0.025	Pseudogene	Unknown	Unknown
ring finger protein 217	RNF217	ENSG00000146373	-7.7	0.009	Protein coding	metal ion binding, ubiquitin-protein transferase activity	Unknown
FKBP prolyl isomerase 1B	FKBP1B	ENSG00000119782	-7.3	0.029	Protein coding	peptidyl-prolyl cis-trans isomerase activity	Unknown

guanylate cyclase 1 soluble subunit alpha 2	*GUCY1A2*	ENSG00000152402	-7.1	0.062	Protein coding	GTP binding, phosphorus-oxygen lyase activity guanylate cyclase activity, heme binding	Intracellular signal transduction, cyclic nucleotide biosynthetic process, positive regulation of cGMP biosynthetic process, adenylate cyclase activity
caveolae associated protein 2	*CAVIN2*	ENSG00000168497	-6.8	0.037	Protein coding	phosphatidylserine binding, phospholipid binding, protein kinase C binding	plasma membrane tubulation
alcohol dehydrogenase 4 (class II), pi polypeptide	*ADH4*	ENSG00000198099	-6.6	0.062	Protein coding	alcohol dehydrogenase (NAD) activity, all-trans retinal binding, ethanol binding, NAD binding	alcohol catabolic process, cellular aldehyde metabolic process, ethanol oxidation
solute carrier family 5 member 11	*SLC5A11*	ENSG00000158865	-6.6	0.025	Protein coding	transporter activity	transmembrane transport
VWA8 antisense RNA 1 (head to head))	*VWA8-AS1*	ENSG00000278338	-6.5	0.025	lncRNA	Unknown	Unknown
NA	*Z98752.2*	ENSG00000234271	-6.5	0.071	Processed pseudogene	Unknown	Unknown
NA	*AC034102.3*	ENSG00000257449	-6.5	0.044	lncRNA	Unknown	Unknown
NA	*AC253536.6*	ENSG00000272787.1	-6.4	0.009	LincRNA	Unknown	Unknown
atypical chemokine receptor 2	*ACKR2*	ENSG00000144648	-6.4	0.074	Protein coding	C-C chemokine receptor activity,	chemotaxis, inflammatory

							scavenger receptor activity, G-protein coupled receptor activity	response, receptor-mediated endocytosis
keratin 74	*KRT74*	ENSG00000170484	-6.3	0.078	Protein coding	keratin filament binding, structural molecule activity	intermediate filament cytoskeleton organization, cornification, keratinization
NA	*RF00019*	ENSG00000252652.1	-6.3	0.009	Y RNA	Unknown	Unknown
protocadherin gamma subfamily B, 8 pseudogene	*PCDHGB8P*	ENSG00000248449	-6.3	0.070	Transcribed pseudogene	Unknown	Unknown
NA	*LOC101928238*	ENSG00000278611	-6.3	0.074	LincRNA	Unknown	Unknown
transmembrane and coiled-coil domains 2	*TMCO2*	ENSG00000188800	-6.2	0.058	Protein coding	Unknown	Unknown
CELF2 antisense RNA 2	*CELF2-AS2*	ENSG00000237986	-6.2	0.052	lncRNA	Unknown	Unknown
NA	*AC013476.1*	ENSG00000234193.1	-6.1	0.025	lncRNA	Unknown	Unknown
pannexin 3	*PANX3*	ENSG00000154143	-5.9	0.074	Protein coding	wide pore channel activity, gap junction hemi-channel activity	cell-cell signalling, transmembrane transport, cation transport
NA	*RF00019*	ENSG00000202222.1	-5.9	0.029	Y RNA	Unknown	Unknown
NA	*LOC101927851*	ENSG00000238005	-5.2	0.088	LincRNA	Unknown	Unknown
leucine rich repeat containing 9	*LRRC9*	ENSG00000131951	-5.2	0.062	Protein coding	Unknown	Unknown

EXTL3 antisense RNA 1	*EXTL3-AS1*	ENSG00000246339	-5.1	0.040	lncRNA	Unknown	Unknown
KIAA2012	*KIAA2012*	ENSG00000182329	-4.6	0.083	Protein coding	Unknown	Unknown
NA	*AC013643.2*	ENSG00000253875	-4.6	0.062	lncRNA	Unknown	Unknown
cytochrome b reductase 1	*CYBRD1*	ENSG00000071967	-4.4	0.052	Protein coding	ferric-chelate reductase activity, protein binding, oxidoreductase activity, oxidizing metal ions	cellular iron ion homeostasis, response to iron ion, oxidation-reduction process
NA	*AC068620.2*	ENSG00000270147	-4.1	0.078	LincRNA	Unknown	Unknown
NA	*AC243428.1*	ENSG00000229979	-4.1	0.037	Processed pseudogene	Unknown	Unknown
stearoyl-CoA desaturase	*SCD*	ENSG00000099194	-2.7	0.058	Protein coding	stearoyl-CoA 9-desaturase activity, iron ion binding, oxidoreductase activity	lipid metabolic process, fatty acid biosynthetic process, regulation of cholesterol biosynthetic process, oxidation-reduction process
NIMA related kinase 10	*NEK10*	ENSG00000163491	-2.2	0.061	Protein coding	nucleotide binding, protein serine/threonine kinase activity, ATP binding, transferase activity	protein phosphorylation, positive regulation of protein autophosphorylation, positive regulation of MAP kinase activity,

							regulation of ERK1 and ERK2 cascade, regulation of cell cycle G2/M phase transition
thymocyte selection associated family member 2	*THEMIS2*	ENSG00000130775	-0.9	0.009	Protein coding	Protein Binding	immune system process, inflammatory response, cell adhesion, T cell receptor signalling pathway
cAMP-dependent protein kinase inhibitor alpha	*PKIA*	ENSG00000171033	-0.5	0.083	Protein coding	protein kinase inhibitor activity, cAMP-dependent protein kinase inhibitor activity,	negative regulation of transcription by RNA polymerase II, negative regulation of protein kinase activity, regulation of G2/M transition of mitotic cell cycle, negative regulation of protein import into nucleus, negative regulation of catalytic activity

849

Upregulated genes in women with PCOS							
Gene name	Gene symbol	ENSEMBL Gene ID	log2Fold Change	padj	Gene name	Molecular function	Molecular process
MX dynamin like GTPase 2	*MX2*	ENSG00000183486	0.6	0.0711	Protein coding	nucleotide binding, GTPase activity, protein binding, microtubule binding	mitochondrial fission, immune system process, defence response, response to virus, response to interferon-alpha, innate immune response, mRNA transport
small Cajal body-specific RNA 21	*SCARNA21*	ENSG00000252835	0.6	0.082652	ScaRNA	Unknown	Unknown
histone cluster 1 H3 family member c	*HIST1H3C*	ENSG00000278272	1.4	0.073504	Protein coding	DNA binding, protein binding, cadherin binding, protein heterodimerization activity	chromatin silencing at rDNA, nucleosome assembly, telomere organization, interleukin-7-mediated signalling pathway, negative regulation of gene expression, epigenetic, regulation of hematopoietic stem cell differentiation, regulation of gene silencing
SMAD family member 1	*SMAD1*	ENSG00000170365	3.0	0.099453	Protein coding	RNA polymerase II proximal promoter sequence-specific DNA binding,	MAPK cascade, mesodermal cell fate commitment, osteoblast fate commitment, inflammatory response, transforming growth factor beta receptor signalling pathway, SMAD protein complex assembly, gamete generation, embryonic pattern specification, BMP signalling pathway

						signal transducer activity, downstream of receptor, transforming growth factor beta receptor, pathway-specific cytoplasmic mediator activity, protein homodimerization activity, co-SMAD binding, I-SMAD binding, primary miRNA binding	

850   Molecular functions and biological processes were established from the Universal Protein Resource (UniProt). False discovery rate (FDR) q<0.1.